Adam Giza, MSc

ST
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany

Poster(s):

• 1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges

• 1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.